Efficacy of thrice-daily biphasic insulin lispro 50/50 in patients with insulin

s vary among patients with diabetes due to insulin For patients whose glycemic goals are not achieved with basal bolus rapid-acting insulin analog regimens , we assigned treatment with basal and /50 (IBB-50). The present study compared the effect of -daily lispro 50/50 combined with insulin glargine in patients with -resistant type 2 diabetes mellitus, was co Thirty-eight patients with type 2 diabetes (aged 30 3 months, HbA1c>8.5%) participated in this study. The study was continued twelve weeks. been treated with stable basal insulin glargine with a -acting insulin analog medication with metformin to basal insulin glargine and thrice-daily biphasic insulin lispro and metformin. The patients had a mean age of 15.7 ± 8.3 years, and an HbA1c of 10.7 -acting insulin analogs were swiched . After 12 weeks, fasting and postprandial were significantly reduced. No serious adverse he IBB-50 therapy may be necessary if patients with type 2 diabetes have high total daily insulin s that are inadequately controlled . words: Biphasic insulin lispro 50, Insulin glargine, Insulin resistance, T